Galectin Therapeutics (GALT) Price & Analysis

Compare

635 Followers

GALT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.73 - $6.55

Previous CloseN/A

Volume135.57K

Average Volume (3M)322.94K

Market Cap

$305.57M

Enterprise Value$242.83M

Total Cash (Recent Filing)$13.77M

Total Debt (Recent Filing)$120.51M

Price to Earnings (P/E)―

Beta0.72

Next Earnings

Nov 17, 2025

EPS Estimate

-0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding64,060,265

10 Day Avg. Volume242,105

30 Day Avg. Volume322,940

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.79

Enterprise Value/Revenue6.75K

Enterprise Value/Gross Profit-80.94K

Enterprise Value/Ebitda-7.24

Forecast

1Y Price Target

$6.00

Price Target Upside25.79% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical PotentialBelapectin 2 mg/kg exhibited a significant positive effect on reducing hepatic venous pressure gradient in patients with MASH cirrhosis without varices at baseline.

Regulatory And Partnership OpportunitiesGalectin's lead asset, belapectin, is currently in development to treat MASH-associated liver cirrhosis and portal hypertension, with ongoing regulatory engagement and potential partnership opportunities.

Unique Treatment OfferingBelapectin is the only therapy in development for MASH cirrhosis and portal hypertension, addressing a patient population with no approved therapies.

Bears Say

Challenges In Clinical TrialsBelapectin's clinical journey has been bumpy, with neither dose achieving the primary endpoint in early trials.

Statistical SignificanceThe composite endpoint in the NAVIGATE trial did not reach statistical significance in the intent-to-treat population.

Galectin Therapeutics News

Galectin Therapeutics Highlights Promising Belapectin Results

An update from Galectin Therapeutics ( ($GALT) ) is now available. On September 8, 2025, Galectin Therapeutics updated...

1M ago

GALT

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Enovix (ENVX) 6.97% +5.59,...

2M ago

ING

AMPY

Galectin Therapeutics Reports Reduced Losses in Q2 2025

Galectin Therapeutics (GALT) ( ($GALT) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

GALT

Optimistic Buy Rating for Galectin Therapeutics Driven by Belapectin’s Potential in Treating Liver Cirrhosis and Strategic Focus

In a report released today, Matthew Keller from H.C. Wainwright reiterated a Buy rating on Galectin Therapeutics, with...

2M ago

GALT

Galectin Therapeutics reports Q2 EPS (12c) vs (20c) last year

Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics (GALT), stated “We are encouraged by the continued...

2M ago

GALT

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Sequans (SQNS) 243.04% +3.42,...

2M ago

ACB

NOK

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Upexi (UPXI) 171.17% +37.21,...

3M ago

BMBL

BZAI

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Microbot Medical (MBOT) 82.20%...

3M ago

VOR

Galectin Therapeutics announces $10M credt line from Richard Uihlein

Galectin Therapeutics (GALT) entered into a new $10M unsecured line of credit facility with Richard E. Uihlein, Chairman...

3M ago

GALT

Galectin Therapeutics Secures $10M Credit Line for Growth

The latest announcement is out from Galectin Therapeutics ( ($GALT) ). On July 8, 2025, Galectin Therapeutics secured...

3M ago

GALT

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Galectin Therapeutics (GALT) 122.54%...

4M ago

CGC

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Galectin Therapeutics (GALT) 128.69%...

4M ago

NFE

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: ChargePoint Holdings (CHPT) 38.00%...

4M ago

CGC

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Sharplink Gaming Inc (SBET)...

4M ago

CGC

JCI

GALT FAQ

What was Galectin Therapeutics (GALT)’s price range in the past 12 months?

Galectin Therapeutics (GALT) lowest stock price was $0.73 and its highest was $6.55 in the past 12 months.

What is Galectin Therapeutics (GALT)’s market cap?

Galectin Therapeutics (GALT)’s market cap is $305.57M.

When is Galectin Therapeutics (GALT)’s upcoming earnings report date?

Galectin Therapeutics (GALT)’s upcoming earnings report date is Nov 17, 2025 which is in 39 days.

How were Galectin Therapeutics (GALT)’s earnings last quarter?

Galectin Therapeutics (GALT) released its earnings results on Aug 14, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.04.

Is Galectin Therapeutics (GALT) overvalued?

According to Wall Street analysts Galectin Therapeutics (GALT)’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Galectin Therapeutics (GALT) pay dividends?

Galectin Therapeutics (GALT) does not currently pay dividends.

What is Galectin Therapeutics (GALT)’s EPS estimate?

Galectin Therapeutics (GALT)’s EPS estimate is -0.11.

How many shares outstanding does Galectin Therapeutics (GALT) have?

Galectin Therapeutics (GALT) has 64,060,265 shares outstanding.

What happened to Galectin Therapeutics (GALT)’s price movement after its last earnings report?

Galectin Therapeutics (GALT) reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went up 2.452%.

Which hedge fund is a major shareholder of Galectin Therapeutics (GALT)?

Currently, no hedge funds are holding shares in GALT

Galectin Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

48.74%

Trailing 12-Months

Asset Growth

-43.58%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Galectin Therapeutics (GALT)

Galectin Therapeutics Inc. is a biotechnology company focused on developing innovative therapies to improve the lives of patients with chronic liver diseases and cancer. The company operates in the biotechnology and pharmaceutical sectors, with a core emphasis on discovering and developing drugs targeting galectin proteins, which are critical in numerous disease processes. Galectin Therapeutics aims to leverage its proprietary technology to create novel treatments, primarily targeting fibrosis and cancer.

Galectin Therapeutics (GALT) Earnings & Revenues

Historic Earnings Reports

GALT Stock 12 Month Forecast

Average Price Target

$6.00

▲(25.79% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","1.75":"$1.75","3.5":"$3.5","5.25":"$5.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.75,3.5,5.25,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Aug<br/>2024","9":"Jan<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.65,3.8307692307692305,4.0115384615384615,4.1923076923076925,4.373076923076923,4.553846153846154,4.734615384615385,4.915384615384616,5.096153846153846,5.276923076923077,5.457692307692308,5.638461538461538,5.819230769230769,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.65,3.8307692307692305,4.0115384615384615,4.1923076923076925,4.373076923076923,4.553846153846154,4.734615384615385,4.915384615384616,5.096153846153846,5.276923076923077,5.457692307692308,5.638461538461538,5.819230769230769,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.65,3.8307692307692305,4.0115384615384615,4.1923076923076925,4.373076923076923,4.553846153846154,4.734615384615385,4.915384615384616,5.096153846153846,5.276923076923077,5.457692307692308,5.638461538461538,5.819230769230769,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.24,"date":1669852800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.65,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >